Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Cemiplimab in relapsed/refractory lymphoma
NCT03769181Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of isatuximab in classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), sponsored by Sanofi. Started Dec 2018; status: terminated.
02
Drugs
isatuximab
03
Conditions
classical Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03769181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769181.